版本:
中国

BRIEF-Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results

Oct 11 Nymox Pharmaceutical Corp

* Nymox reports successful new phase 3 long-term fexapotide repeat injection bph trial results: lasting symptomatic improvement up to 6 years after single repeated treatment

* Nymox pharmaceutical - Results show there was long-term statistically significant symptomatic improvement compared to phase 3 patients who received placebo alone Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐